Pages that link to "Q39379624"

The following pages link to Role of epigenetics-microRNA axis in drug resistance of multiple myeloma (Q39379624):

Displaying 17 items.

• Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis (Q44027685) (← links)
• Evolutionary biology of high-risk multiple myeloma (Q47913337) (← links)
• Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma (Q50318733) (← links)
• Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. (Q52630284) (← links)
• EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. (Q55018505) (← links)
• Abnormal microRNA expression in the course of hematological malignancies (Q57817341) (← links)
• Role of microRNAs in inner ear development and hearing loss (Q58591674) (← links)
• NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma (Q58595932) (← links)
• Histone deacetylase 6 in cancer (Q58768571) (← links)
• EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies (Q59790124) (← links)
• MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6 (Q64058384) (← links)
• HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells (Q64062830) (← links)
• Noncoding RNAs in cancer therapy resistance and targeted drug development. (Q64916710) (← links)
• Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies (Q89185076) (← links)
• Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance (Q90324835) (← links)
• The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies (Q91229404) (← links)
• m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis (Q91819611) (← links)